HS130- 001 1 of 60 Version 2.0 - 11 Feb 2020 Confidential - Entire Page A Phase I, first -in-human, dose -escalation study to evaluate the safety and immunologic response after administration of HS -130 in combination with HS -110 (viagenpumatucel -L) in patients with solid tumors refractory to standard care Protocol No.: HS130 -001 IND No.: 19098 Principal Investigator: Rachel E. Sanborn , MD Providence Cancer Institute, Portland, OR, USA Sponsor: Heat Biologics 627 Davis Drive, Suite 400 Morrisville , NC 27560 (919) 240 -7133 Medical Monitor: Vance Y. Sohn MD (253) 722-3144 vsohn@cancerinsight.com Protocol Version: 2.0 Replaces: 1.2 Date: 11 February 2020 CONFIDENTIAL This document contains strictly confidential information and cannot be disclosed or used, unless authorized in writing by Heat Biologics . HS130-001 2 of 60 Version 2.0 - 11 Feb 2020 Confidential - Entire Page INVESTIGATOR’S STATEMENT 1. I have carefully read this protocol entitled “ A Phase I, first -in-human, dose -escalation study to evaluate the safety and immunologic response after administration of HS -130 in combination with HS -110 (viagenpumatucel- L) in patients with solid tumors refractory to standard care” and agree that it contains all the necessary information required to conduct the study. I agree to conduct this study as outlined in the protocol.